Ascelia Pharma AB (publ) (ACE) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.137x

Based on the latest financial reports, Ascelia Pharma AB (publ) (ACE) has a cash flow conversion efficiency ratio of -0.137x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-15.66 Million ≈ $-1.69 Million USD) by net assets (Skr114.40 Million ≈ $12.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Ascelia Pharma AB (publ) - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Ascelia Pharma AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ACE total debt and obligations for a breakdown of total debt and financial obligations.

Ascelia Pharma AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ascelia Pharma AB (publ) ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Jindalee Lithium Ltd AU:JLL	-0.060x
Ajinextek Co. Ltd KQ:059120	0.027x
DT Cloud Star Acquisition Corporation Ordinary Shares NASDAQ:DTSQ	-0.001x
Firetail Resources Ltd AU:FTL	-0.038x
ROK Resources Inc V:ROK	0.058x
SIFCO Industries Inc NYSE MKT:SIF	0.209x
Honmyue Enterprise Co Ltd TW:1474	0.029x
Mineralbrunnen Überkingen-Teinach GmbH & Co. KGaA F:MUT3	0.031x

Annual Cash Flow Conversion Efficiency for Ascelia Pharma AB (publ) (2017–2024)

The table below shows the annual cash flow conversion efficiency of Ascelia Pharma AB (publ) from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Ascelia Pharma AB (publ) worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr78.94 Million ≈ $8.50 Million	Skr-62.84 Million ≈ $-6.76 Million	-0.796x	+53.33%
2023-12-31	Skr74.33 Million ≈ $8.00 Million	Skr-126.79 Million ≈ $-13.64 Million	-1.706x	-146.30%
2022-12-31	Skr180.86 Million ≈ $19.46 Million	Skr-125.26 Million ≈ $-13.48 Million	-0.693x	-82.92%
2021-12-31	Skr307.83 Million ≈ $33.13 Million	Skr-116.56 Million ≈ $-12.54 Million	-0.379x	-4.51%
2020-12-31	Skr236.06 Million ≈ $25.40 Million	Skr-85.53 Million ≈ $-9.20 Million	-0.362x	-132.65%
2019-12-31	Skr237.06 Million ≈ $25.51 Million	Skr-36.92 Million ≈ $-3.97 Million	-0.156x	-41.74%
2018-12-31	Skr276.07 Million ≈ $29.71 Million	Skr-30.33 Million ≈ $-3.26 Million	-0.110x	+41.43%
2017-12-31	Skr111.73 Million ≈ $12.02 Million	Skr-20.96 Million ≈ $-2.26 Million	-0.188x	--

About Ascelia Pharma AB (publ)

ST:ACE Sweden Biotechnology

Market Cap

$40.96 Million

Skr380.61 Million SEK

Market Cap Rank

#22609 Global

#421 in Sweden

Share Price

Skr3.00

Change (1 day)

+2.04%

52-Week Range

Skr2.60 - Skr5.10

All Time High

Skr900.24